Repeat: Treatment.com AI Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated Patients
VANCOUVER, BC, June 11, 2025 (GLOBE NEWSWIRE) —
Treatment.com
AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of
Treatment.com
AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs).
The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow.
'Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.' stated Dr. Kevin Peterson, Founder and Chief Medical Officer of
Treatment.com
AI. 'The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we're helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.'
The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables:
'Partnering with
Treatment.com
AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.' said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. 'We look forward to sharing our findings.'
The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results.
Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program.
Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.
About
Treatment.com
AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally,
Treatment.com
AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support.
Treatment.com
AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at:
or contact
.
About University of Minnesota Medical School
Founded in 1888, the University of Minnesota Medical School is one of the nation's largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations.
Learn more at:
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO –
Treatment.com
AI Inc.
Email:
Media inquiries:
treatment.com
Sales:
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on
Treatment.com
AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although
Treatment.com
AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and
Treatment.com
undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
6 hours ago
- Hamilton Spectator
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) in an oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine, and an investigator in the TUSCANY study, reported safety and efficacy data from the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet. Dr. Mannis also noted three patients were rapidly enrolled on the third dose cohort of 120 mg TUS in the TUS+VEN+AZA triplet, and that no DLTs have been observed to date. The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Key findings: 'The TUSCANY triplet trial is well under way, and we are observing exciting activity with the addition of TUS to the VEN+AZA standard treatment,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. 'The data presented today reveal complete responses across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. TUS appears to have tremendous opportunity in the largest markets and the most challenging of AML cases.' Abstracts are available on the EHA2025 website here . The presentation is available on the Aptose website here . TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS, is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on ( here ). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit . Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@
Yahoo
8 hours ago
- Yahoo
UBS identifies stock winners amid structural growth tailwinds
-- In a note to clients on Thursday, UBS analysts assessed "The Next Big Thing" in global equities, focusing on companies that leverage technology to disrupt various sectors. Through their "Global equity focus list," UBS anticipates "strong structural growth drivers to enable our recommendations to outperform the broader market". The investment theme highlights "greentech, enabling tech, fintech, and healthtech sectors," which UBS views as "leading disruptors in sectors undergoing technological transformation, which should lead to consequential and enduring impact". These stocks are collectively "expected to deliver superior earnings growth to the market, boosted by positive, durable structural trends supporting the theme". In enabling technology, UBS predicts significant growth, with the sector "projected to grow to USD 1.2 trillion by 2025, i.e., 15% CAGR from FY20-25". They "expect investors to benefit from increased tech spending and resulting strong revenue growth for the next few years," with Meta Platforms (NASDAQ:META), Alibaba (NYSE:BABA), Oracle Corporation (NYSE:ORCL), and Microsoft (NASDAQ:MSFT) among the names in its focus list. Greentech is supported by "long-term policy support as major economies work toward reducing carbon emissions and reaching net-zero targets." Rolls-Royce (OTC:RYCEY) is one of the names on the focus list. Fintech fundamentals "remain strong, supported by positive net interest income trends."UBS said Barclays was a top gainer in this area, while Euronext (EPA:ENX) NV is also on the list. While healthtech has seen challenges, UBS sees "significant catch-up potential, and generative A.I. progress should act as another catalyst," noting AstraZeneca (NASDAQ:AZN) as a top gainer. Alcon (NYSE:ALC) and Intuitive Surgical (NASDAQ:ISRG) are other healthtech names featured. Related articles UBS identifies stock winners amid structural growth tailwinds Activist investor Palliser Capital reportedly builds 5% stake in WH Smith Citi highlights sector opportunities based on recent flows
Yahoo
8 hours ago
- Yahoo
Bion's Technology-Optimization Report Details Success of Ammonia Recovery System
Billings, Montana, June 12, 2025 (GLOBE NEWSWIRE) -- Bion Environmental Technologies, Inc. (OTC QB: BNET), a leader in advanced livestock and organic waste treatment and resource recovery technology, announced it has completed the Technology-Optimization Report for its Ammonia Recovery System (ARS) at Fair Oaks, IN. The optimized ARS demonstrated it is stable and can maintain continuous steady-state operations; it is reliable; and it is scalable. The ARS also showed it can achieve its ammonia reduction targets by evaporating one-third less water than was anticipated and modeled. That translates to significantly better economics, including lower fertilizer production costs. The platform is now ready for the final design process of a full-scale commercial system, which is subject to project-specific details, location, and feedstock characteristics. Bion is currently evaluating more than two dozen potential projects, with dozens more in the pipeline. The Report details over a decade of ARS concept development and technology R&D, with an emphasis on what was accomplished during the optimization phase at Fair Oaks. Bion engaged Buflovak, a New York engineering firm, as its ARS development partner, due to their specific expertise in evaporation, distillation, and separation processes. The Buflovak engineering team was integrally involved during six years of ARS R&D and testing, including providing guidance during the 18-month optimization phase at Fair Oaks, and a final review of the Report. The Buflovak engineering team is available to discuss the report and its conclusions. Economics were not evaluated during optimization, but the substantial operational improvements that were achieved have a direct impact on modeled system economics and fertilizer production costs. Fair Oaks results indicate operating costs for a full-scale commercial system will be about 25% lower than previously modeled, with a corresponding decrease in fertilizer production costs. Modeled capital cost, either overall or as a function of fertilizer or treatment capacity, will decrease significantly, as well. Craig Scott, Bion's CEO, said, 'As we have indicated for some time, the ARS has exceeded our expectations. This report details by just how much. To our Chief Technology Officer, Steve Pagano, the rest of the Bion Team, and our engineering partners at Buflovak: Congrats! What a great time to overdeliver! We are now sorting through and evaluating dozens of potential projects and partners to find the best fit to fill our initial fertilizer offtake agreements. Our goal is to identify a project (or projects) that will allow us to supply our unique organic nitrogen fertilizer to growers during the 2026 growing season.' Click here to view the Report Summary, including its Conclusions, on our website. Click here to download in pdf. The full report is available under non-disclosure agreement and can be obtained by contacting Bion. Bion Environmental Technologies' patented Ammonia Recovery System (ARS) produces organic (OMRI Listed) and low-carbon nitrogen fertilizers from the problematic ammonia produced when biogas is generated from animal manure, industrial, and other organic waste streams. Recovering this valuable resource, instead of allowing it to escape to the environment, prevents air and water pollution, produces clean water for reuse or discharge, and improves the economics of livestock and biogas operations. Bion's platform aligns with global trends toward circular economy models and low-carbon and low-impact fuels and agriculture. See Bion's website at This material includes forward-looking statements based on management's current reasonable business expectations. In this document, the words and phrases like 'will', 'can', and similar expressions identify certain forward-looking statements. These statements are made in reliance on the Private Securities Litigation Reform Act, Section 27A of the Securities Act of 1933, as amended. There are numerous risks and uncertainties that could result in actual results differing materially from expected outcomes. Contact Information:Craig Scott, CEOcscott@ (406) 281-8178 (direct)
